SPP635

Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Next Generation Renin Inhibitor to Continue Phase II Profiling in Diabetic Patients BASEL/Switzerland and BRIDGEWATER NJ/USA, 28 June 2007-Speedel (SWX: SPPN) today announced that it has reached another significant milestone in the development of its family of renin inhibitors with the succes...

SPP635 in other areas

Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in ...

... tolerability of two different doses of SPP635 in type II diabetic patients with ... Drug: SPP635. Phase II. Study Type: Interventional. Study Design: ...

Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate ...

Drug: SPP635 (drug) Phase II. Study Type: Interventional. Study Design: ... This study investigates the safety and efficacy of a novel oral renin inhibitor, SPP635. ...

Speedel Begins Phase IIa Trial With Next Generation Renin Inhibitor

... of a Phase IIa clinical trial with SPP635 for the treatment of hypertension. ... SPP635 Successfully Completes Phase I Safety and Tolerability Study ...

Controlling Hypertension With Legislation, Employer Programs ...

Development of Second-Generation Renin Inhibitor Continues in Hypertensive Patients With ... Speedel reports successful SPP635 phase IIa trial in hypertension. ...

SPEEDEL REPORTS ON DATA PUBLISHED AT HYPERTENSION 2008 MEDICAL ...

Speedel Holding AG New pre-clinical and clinical data for SPP635 and SPP301 ... Compared to placebo, SPP635 was more efficacious in lowering blood pressure, ...

SWISS BIOTECH 2009

SPP635 is the most advanced compound in the SPP600 series and is one of several ... SPP635 was safe and well tolerated over the 4 week period. ...